Skip to main content

Table 5 Most frequent (≥5% of patients) grade 3–4 treatment-emergent adverse events (TEAEs)

From: Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens

Preferred term Azacitidine (n = 128) n (%) CCR (n = 130) n (%)
Any grade 3–4 TEAE 111 (87) 113 (87)
Thrombocytopenia 33 (26) 27 (21)
Febrile neutropenia 29 (23) 43 (33)
Neutropenia 28 (22) 25 (19)
AML* 25 (20) 23 (18)
Pneumonia 24 (19) 18 (14)
Anaemia 19 (15) 21 (16)
Pyrexia 13 (10) 9 (7)
Hypokalaemia 9 (7) 10 (8)
Leukopenia 8 (6) 10 (8)
Sepsis 7 (6) 9 (7)
Decreased appetite 6 (5) 2 (2)
Dyspnoea 6 (5) 4 (3)
  1. Safety-evaluable patients received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. Patients who received BSC only were included in safety assessments if they had at least 1 post-randomisation safety assessment
  2. *Worsening disease